EQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.

Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)

CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future

Dreieich, Germany, 6 March 2025. The Board of Management of Biotest AG announces that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025.

The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future.

Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.

Biotest Aktiengesellschaft
The Board of Management
 

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich

www.biotest.com

Disclaimer

This document contains forward-looking statements on the overall economic development and the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on the company's current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties that could cause actual developments to differ materially from those anticipated. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and does not assume any obligation to do so.

About Biotest

Biotest (www.biotest.com) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,500 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Biotest has been a part of the Grifols Group, headquartered in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Contact: